Author: Martha K Berg; Qinggang Yu; Cristina E Salvador; Irene Melani; Shinobu Kitayama
Title: Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19 Document date: 2020_4_7
ID: 44zlnswd_2
Snippet: The BCG vaccine is used primarily against tuberculosis (4) . One review has found that BCG vaccination reduces the risk of tuberculosis by 50% (5) . A follow-up of an earlier BCG clinical trial performed on native Americans show that BCG protects people from both tuberculosis and lung cancer for up to several decades, throughout each person's life (2, 3) . A more recent meta-analysis of a broader range of observational studies and clinical trials.....
Document: The BCG vaccine is used primarily against tuberculosis (4) . One review has found that BCG vaccination reduces the risk of tuberculosis by 50% (5) . A follow-up of an earlier BCG clinical trial performed on native Americans show that BCG protects people from both tuberculosis and lung cancer for up to several decades, throughout each person's life (2, 3) . A more recent meta-analysis of a broader range of observational studies and clinical trials (1) suggests that the effectiveness of BCG could extend to all-cause mortality. Several controlled trials provide consistent results, showing that the reduced mortality is attributable to protection against respiratory infections, as well as neonatal sepsis (6) (7) (8) . Altogether, the available evidence suggests that BCG has beneficial effects on immunity against a range of lung-related infections that go beyond tuberculosis, which makes it a promising candidate for defending against COVID-19. As for mechanisms, recent experimental work (9) finds that BCG vaccination causes genome-wide epigenetic reprogramming of human monocytes, which in turn predicts protection against experimental viral infection.
Search related documents:
Co phrase search for related documents- available evidence and BCG vaccine: 1, 2
- available evidence and beneficial effect: 1, 2, 3, 4, 5, 6, 7, 8
- available evidence and broad range: 1, 2, 3, 4
- available evidence and cause mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
- available evidence and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- available evidence and control trial: 1, 2, 3, 4, 5, 6
- available evidence and lung cancer: 1, 2, 3, 4, 5, 6
- available evidence and neonatal sepsis: 1
- available evidence and observational study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- available evidence and person life: 1
- available evidence and promising candidate: 1
- available evidence and reduced mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- available evidence and respiratory infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- available evidence and respiratory infection protection: 1, 2
- available evidence and tuberculosis risk: 1
- available evidence and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44
- BCG effectiveness and beneficial effect: 1
- BCG effectiveness and clinical trial: 1
- BCG effectiveness and respiratory infection: 1, 2
Co phrase search for related documents, hyperlinks ordered by date